Sarepta Stock Yo-Yoes After Winning Highly Anticipated Gene Therapy NodInvestors Business Daily • 06/22/23
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular DystrophyBusiness Wire • 06/22/23
Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?Zacks Investment Research • 06/01/23
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?The Motley Fool • 06/01/23
Sarepta Therapeutics shares fall as FDA delays decision on gene therapyProactive Investors • 05/24/23
Sarepta Therapeutics Dives On An Unexpected Hold-Up For Its Gene TherapyInvestors Business Daily • 05/24/23
Sarepta says FDA is working toward accelerated approval of its latest treatment for Duchenne muscular dystrophyMarket Watch • 05/24/23